X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (598) 598
Publication (58) 58
Conference Proceeding (15) 15
Patent (7) 7
Book Chapter (4) 4
Book / eBook (3) 3
Book Review (2) 2
Data Set (2) 2
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (265) 265
index medicus (252) 252
oncology (186) 186
male (161) 161
cancer (156) 156
chemotherapy (115) 115
urology & nephrology (111) 111
aged (109) 109
female (107) 107
middle aged (100) 100
urology (93) 93
metastasis (86) 86
bladder cancer (85) 85
treatment outcome (80) 80
care and treatment (68) 68
antineoplastic combined chemotherapy protocols - therapeutic use (66) 66
survival (63) 63
antineoplastic agents - therapeutic use (62) 62
carcinoma (60) 60
prognosis (56) 56
hematology, oncology and palliative medicine (55) 55
aged, 80 and over (54) 54
adult (53) 53
prostate cancer (53) 53
urothelial carcinoma (53) 53
transitional-cell carcinoma (49) 49
carcinoma, renal cell - drug therapy (45) 45
kidney neoplasms - drug therapy (45) 45
analysis (42) 42
cisplatin (41) 41
disease-free survival (41) 41
urinary bladder neoplasms - drug therapy (41) 41
therapy (40) 40
urinary bladder neoplasms - pathology (40) 40
docetaxel (39) 39
sunitinib (39) 39
survival analysis (38) 38
carcinoma, transitional cell - drug therapy (36) 36
immunotherapy (34) 34
neoplasm metastasis (34) 34
research (34) 34
urologic neoplasms - drug therapy (34) 34
drug therapy (33) 33
phase-ii trial (32) 32
renal cell carcinoma (32) 32
tumors (32) 32
interferon-alpha (31) 31
kidney neoplasms - pathology (31) 31
bladder-cancer (30) 30
article (29) 29
bevacizumab (29) 29
double-blind (28) 28
retrospective studies (28) 28
trial (28) 28
medical colleges (27) 27
clinical trials (26) 26
neoplasm staging (26) 26
prognostic-factors (26) 26
sorafenib (26) 26
urologic neoplasms - pathology (26) 26
phase-iii trial (25) 25
risk factors (25) 25
antineoplastic agents (24) 24
carcinoma, renal cell (24) 24
gemcitabine (24) 24
antimitotic agents (22) 22
carcinoma, transitional cell - pathology (22) 22
patients (22) 22
prostatic neoplasms - pathology (22) 22
radical cystectomy (22) 22
cancer therapies (21) 21
carcinoma, renal cell - secondary (21) 21
kaplan-meier estimate (21) 21
urinary bladder neoplasms - mortality (21) 21
urothelium - pathology (21) 21
cystectomy (20) 20
open-label (20) 20
paclitaxel (20) 20
phase-ii (20) 20
development and progression (19) 19
disease progression (19) 19
drug administration schedule (19) 19
multicenter (19) 19
mutation (19) 19
survival rate (19) 19
urinary bladder neoplasms - surgery (19) 19
efficacy (18) 18
everolimus (18) 18
patient outcomes (18) 18
prostatic neoplasms, castration-resistant - drug therapy (18) 18
radiotherapy (18) 18
urinary bladder neoplasms - therapy (18) 18
antineoplastic combined chemotherapy protocols - adverse effects (17) 17
carcinoma, renal cell - pathology (17) 17
proportional hazards models (17) 17
prostatic neoplasms - drug therapy (17) 17
prostatic neoplasms - therapy (17) 17
chemotherapy, adjuvant (16) 16
clinical trials as topic (16) 16
deoxycytidine - analogs & derivatives (16) 16
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet, ISSN 0140-6736, 11/2017, Volume 390, Issue 10109, pp. 2220 - 2221
Angiogenesis has been associated with clinicopathological factors and features of biological aggressiveness in urothelial cancer.1,2 Although several agents... 
RAMUCIRUMAB | TRIAL | MEDICINE, GENERAL & INTERNAL | THERAPY | PHASE-II | OPEN-LABEL | CARCINOMA | Urinary Bladder Neoplasms | Carcinoma, Transitional Cell | Angiogenesis Inhibitors | Humans | Immunotherapy | Urothelial cancer | Angiogenesis | Chemotherapy | Medical prognosis | Metastasis | Vascular endothelial growth factor | Cancer therapies
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10031, pp. 1909 - 1920
Journal Article
Biomedicines, ISSN 2227-9059, 08/2018, Volume 6, Issue 3, p. 85
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10064, pp. 67 - 76
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 23, p. 2304
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 12, pp. 1143 - 1150
Summary Background Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell carcinoma, but some patients do not respond or need dose... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | VARIABILITY | INTERFERON-ALPHA | EFFICACY | ANGIOGENESIS | BIOMARKER | ONCOLOGY | GENOTYPE | VEGF | EXPRESSION | EXPOSURE | Predictive Value of Tests | Kidney Neoplasms - genetics | Prospective Studies | Humans | Middle Aged | Carcinoma, Renal Cell - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Patient Selection | Sunitinib | Cytochrome P-450 CYP3A - genetics | Time Factors | Antineoplastic Agents - adverse effects | Pyrroles - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Precision Medicine | Protein Kinase Inhibitors - pharmacokinetics | Genetic Predisposition to Disease | Risk Assessment | Carcinoma, Renal Cell - pathology | Gene Frequency | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Spain | Disease-Free Survival | Homozygote | Phenotype | Indoles - adverse effects | Protein Kinase Inhibitors - therapeutic use | Heterozygote | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Polymorphism, Single Nucleotide | Kidney Neoplasms - drug therapy | Vascular Endothelial Growth Factor Receptor-3 - genetics | Genetic markers | Carcinoma | Toxicity | Oncology | Single-nucleotide polymorphism | Gene polymorphism | Protein-tyrosine kinase | Survival | Interleukin 8 | Vascular endothelial growth factor receptors | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1307 - 1316
Journal Article
Expert Opinion on Biological Therapy, ISSN 1471-2598, 07/2019, Volume 19, Issue 7, pp. 685 - 695
Introduction: Successful results of immuno-oncological drugs in metastatic urothelial cancer have triggered the interest of researchers to test them in the... 
neoadjuvant | NMIBC | biomarkers | bladder cancer | immunotherapy | MIBC | radical cystectomy | Adjuvant | urothelial cancer
Journal Article